The U.S. Food and Drug Administration (FDA) has announced a voluntary recall of Chantix after testing found elevated levels of nitrosamines\u2014compounds that can increase cancer risk with long-term exposure.<\/p>\n
Although the exact risk to patients is still unclear, the levels exceeded safety guidelines, prompting precautionary action. The recall was carried out with the manufacturer to remove affected batches and maintain trust in the drug supply.<\/p>\n
Chantix is widely used to help people quit smoking, so its temporary shortage may impact patients. Health professionals are advised to contact those affected, and patients should consult their doctors about alternatives rather than stop treatment abruptly.<\/p>\n
The FDA also urged stronger testing across the pharmaceutical industry, noting similar issues in other medications. Officials emphasized that the recall reflects a commitment to safety, even when risks are not fully certain.<\/p>\n","protected":false},"excerpt":{"rendered":"